Silence Therapeutics (SLN) Set to Post Earnings on Thursday

Key Points

• Silence Therapeutics is expected to report Q3 2026 results before the market opens Thursday, November 5. Analysts forecast a loss of $0.1129 per share and revenue of approximately $0.11 million.
• The company’s previous quarter fell short of expectations, reporting a $0.26-per-share loss versus the $0.14 loss analysts anticipated. Analysts expect full-year and next-year losses of $0.82 and $0.94 per share, respectively.
• Shares opened at $19.71, near their 12-month high of $19.86, while analyst sentiment remains cautious: SLN carries a consensus “Hold” rating and an average price target of $24.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) is projected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.1129) per share and revenue of $0.11 million for the quarter. Parties can find conference call details on the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 2:00 AM ET.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. On average, analysts expect Silence Therapeutics to post ($0.82) EPS for the current fiscal year and ($0.94) EPS for the next fiscal year.

Silence Therapeutics Trading Down 0.4%

Shares of NASDAQ SLN opened at $19.71 on Thursday. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -15.40 and a beta of 1.45. Silence Therapeutics has a 12 month low of $4.19 and a 12 month high of $19.86. The stock has a 50-day moving average price of $13.23 and a two-hundred day moving average price of $8.90.

Wall Street Analyst Weigh In

SLN has been the topic of a number of research analyst reports. William Blair downgraded shares of Silence Therapeutics from an "outperform" rating to a "hold" rating in a research note on Monday, October 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Silence Therapeutics in a research report on Thursday, October 15th. Jefferies Financial Group cut shares of Silence Therapeutics from a "buy" rating to a "hold" rating and set a $20.00 price objective for the company. in a research report on Monday, October 19th. Morgan Stanley increased their price objective on shares of Silence Therapeutics from $25.00 to $32.00 and gave the company an "overweight" rating in a research note on Tuesday, August 11th. Finally, HC Wainwright lowered shares of Silence Therapeutics from a "buy" rating to a "neutral" rating and cut their target price for the company from $75.00 to $20.00 in a research report on Wednesday, October 21st. Two analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Silence Therapeutics presently has an average rating of "Hold" and an average target price of $24.00.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its approach is designed to intervene at the genetic messenger RNA stage, potentially providing targeted and durable effects for patients with serious diseases.

The company's proprietary mRNAi GOLD platform supports the design and delivery of siRNA medicines, including compounds intended to target tissues such as the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.